- Speaker : Amorit Education
- Session Code : AEJUN0126
- Date : June 2026
- Time : N/A
- Duration : 30 Mins
Free Webinar - FDA Warning Letter on AI Reliance: CGMP Documentation, Quality Unit Review, and Human Accountability
Scroll to the bottom to watch the entire 30 mins explainer
Overview
Artificial
intelligence is quickly becoming part of regulated manufacturing workflows, but
FDA-regulated companies cannot allow AI output to replace CGMP judgment,
quality unit review, process validation, or documented evidence of compliance.
This
webinar uses FDA’s 2026 warning letter involving AI-assisted CGMP documentation
as a practical learning point for quality, regulatory, validation,
manufacturing, laboratory, document control, and compliance teams. The issue is
not that FDA is against AI. The issue is whether AI-generated or AI-assisted
content is properly verified, reviewed, approved, controlled, and documented
before it enters a regulated workflow.
The
session explains why unverified AI output can create serious compliance
exposure when it is used for SOPs, specifications, master production records,
validation decisions, regulatory interpretation, or other quality-impacting
documents. It also outlines practical prevention steps, including AI use SOPs,
risk classification, human-in-the-loop review, quality unit approval, review
trails, document control, CAPA, and inspection-ready evidence.
Areas Covered:
- What
FDA said about over-reliance on AI in CGMP documentation
- Why
the warning letter should not be treated as an anti-AI message
- Why
AI cannot replace CGMP judgment, quality unit oversight, or documented evidence
- How
AI-assisted specifications, procedures, and master production records can
create risk
- Why
polished AI output is not the same as compliant output
- Why
“the AI did not tell us” is not a defensible CGMP position
- Quality
unit responsibilities when AI is used in regulated workflows
- Process
validation concerns when AI-generated content misses required steps
- How
to classify AI use cases by risk and context of use
- Lower-risk,
higher-risk, and very high-risk AI use cases in GxP/CGMP environments
- Human
verification, SME review, QA/QC review, and quality unit approval
- Building
an AI use SOP for GxP and CGMP activities
- Creating
an AI inventory across quality, regulatory, validation, manufacturing, lab,
document control, and training
- Document
control expectations for AI-assisted SOPs, specifications, and master records
- Capturing
the prompt, AI output, reviewer comments, source verification, changes,
approval date, and final approver
- Change
control, version control, and training requirements for AI-assisted documents
- CAPA
questions for AI-related errors, omissions, and uncontrolled documents
- Evidence
an inspector may expect to see for AI governance
- Practical
checklist for bringing AI use under quality system control
Why
Should You Attend?
AI
can help regulated companies move faster, but speed without control can create
CGMP exposure. A document may look complete, polished, and professional while
still missing a required validation step, testing requirement, quality unit
approval, or current regulatory expectation.
This
session helps attendees understand where AI use becomes risky in FDA-regulated
manufacturing and how to prevent AI-assisted content from entering the quality
system without proper oversight. The focus is practical: how to verify AI
output, assign accountability, document human review, involve the quality unit,
and keep AI governance inside the pharmaceutical quality system rather than
treating it as a separate IT issue.
Attendees
will leave with a clearer framework for using AI responsibly in CGMP work: let
AI assist the work, but never let AI become the accountable quality decision
maker.
Who
Will Benefit?
This
webinar is designed for professionals involved in FDA-regulated quality
systems, CGMP documentation, validation, regulatory compliance, manufacturing
controls, document approval, and inspection readiness. Those include:
- Quality
Assurance Managers
- Quality
Assurance Specialists
- Quality
Control Managers
- Quality
Unit Personnel
- Regulatory
Affairs Professionals
- CGMP
Compliance Managers
- Validation
Managers
- Process
Validation Specialists
- Computer
System Validation Teams
- Manufacturing
Managers
- Production
Managers
- Laboratory
Managers
- Document
Control Teams
- Change
Control Managers
- CAPA
Managers
- Training
Managers
- Internal
Auditors
- GxP
Compliance Professionals
- Pharmaceutical
Quality System Leaders
- Drug
Manufacturing Compliance Teams
- Contract
Manufacturing Oversight Teams
- Supplier
Quality Professionals
- Data
Integrity Professionals
- FDA
Inspection Readiness Teams
- Regulatory
Counsel
- CGMP
Consultants
- Life
Sciences Compliance Leaders
- Biotech Quality Teams
- Pharmaceutical Manufacturing Executives
Watch the entire 30 mins explainer here:
This webinar is presented by Amorit Education’s in-house experts, who closely monitor FDA regulatory, compliance, quality system, and industry developments affecting medical device, pharmaceutical, biotechnology, and other life sciences organizations. Their work is focused on turning complex FDA and regulatory updates into practical guidance that helps quality, regulatory, compliance, operations, and business teams understand what has changed, why it matters, where risks may emerge, and what actions may deserve closer attention.
For this session, the focus is on helping medical device professionals understand the practical impact of QMSR, including how quality systems, risk management, supplier oversight, complaint handling, CAPA, UDI, internal audits, and management review may need to work together under current FDA expectations.